Ophthalmology Times6d
FDA accepts new drug application for low-dose atropine from Sydnexis
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
Yahoo Finance14d
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
filed its New Drug Application (NDA) submission for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA ...
FDA files Corcept’s NDA for Relacorilant as treatment in Hypercortisolism
Corcept Therapeutics (CORT) announced that the FDA filed its New Drug Application (NDA) submission for its proprietary, selective cortisol ...
Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA
In a regulatory filing, Cytokinetics (CYTK) disclosed that at upcoming investor conferences, the company will be providing, and is hereby ...